25 May 2018 - A court has dismissed an Australian Competition and Consumer Commission appeal in a case in which it alleged Pfizer had used its market power to limit competition for its cholesterol-lowering drug Lipitor.

The ACCC said on Friday it was considering the judgment and remained committed to pursuing cases involving "misuse of market power".

"The ACCC brought this appeal because it was concerned that Pfizer's use of its market position as supplier of the top-selling branded atorvastatin immediately before generic products were able to enter the market harmed the competitive process and therefore consumers," chairman Rod Sims said in a statement.

Read Sydney Morning Herald article